(firstQuint)Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Diabetic Macular Edema.

 Participants with diabetic macular edema will be treated with one injection of intravitreal infliximab (2.

0mg/0.

05ml) and followed for three months.

 Outcomes that be assessed include best-corrected visual acuity, macular thickness as measured by optical coherence tomography, and electroretinogram responses.

.

 Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Diabetic Macular Edema@highlight

The purpose of this study is to determine if intravitreal infliximab is a safe and effective treatment for macular edema secondary to diabetes.

